Please assess the completion status of the following clinical trial:

Trial Title: The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is ≥ 18 years of age.~* Patient has a panel reactive antibody (PRA) ≥ 70% at any time prior to screening.~* Patient is considered compliant and intends to be available for a minimum follow-up study period of 1 year.~* Patient must be vaccinated against Neisseria meningitides at least 2 weeks prior to receiving treatment therapy or receive appropriate antibiotic prophylaxis for the duration of eculizumab treatment if timely vaccination could not be achieved prior to transplantation.~* Voluntary written informed consent must be obtained before performance of any study-related procedure not considered routine medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.~* Female subject is either post-menopausal or surgically sterilized or willing to use two acceptable methods of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study and for up to 2 months after the last dose of study medication.~Exclusion Criteria:~* Donor or recipient age is \< 18 years or \> 75 years.~* Cold ischemia time is \> 6 hours.~* Current clinical, radiographic, or laboratory evidence of active or latent tuberculosis (TB), as determined by local standard of care.~* History of active TB within the last 2 years, even if treated.~* History of active TB greater than 2 years ago, unless there is documentation of adequate treatment according to locally accepted clinical practice.~(Note: Patients at risk of TB reactivation preclude administration of conventional immunosuppression, as determined by the study investigator and based upon appropriate evaluation).~* Receipt of desensitization treatment with rituximab less than 2 weeks prior to therapy and cluster of differentiation antigen 20 (CD20) count \>2%.~* Receipt of a live vaccine within 4 weeks prior to study entry.~* Patients with current or recent severe systemic infections within the 2 weeks prior to transplantation.~* Prior history of splenectomy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Eculizumab (Type: EXPERIMENTAL): Administration of Eculizumab to heart transplant recipients at Cedars Sinai Medical Center with a panel reactive antibody (PRA) ≥ 70%, for the prevention of antibody-mediated rejection.

Based on this trial design, predict the completion outcome and termination type (if applicable).